Sterile Liquid Product Manufacture
A dedicated facility capable of manufacture of sterile liquid products for early stage clinical studies.
Construction of a new facility (to be licenced by the MHRA) for the manufacture of sterile liquid products is currently underway.
Sitting alongside the API facility in the QMRI, this new addition to HTAF services will enable rapid and cost effective final product manufacture for use in early stage clinical studies.
We expect this facility to be operational and available for use by Q3 2021.
